公开(公告)号：US20240293425A1

公开(公告)日：2024-09-05

申请号：US18564894

申请日：2022-06-03

Applicant: University of Cincinnati ,  UWM Research Foundation, Inc.

Inventor： Daniel Pomeranz Krummel ,  Soma Sengupta ,  James M. Cook ,  Taukir Ahmed ,  Aniruddha Karve ,  Laura Kallay ,  Pankaj Desai ,  Debanjan Bhattacharya ,  Donatien Kamdem Toukam ,  Riccardo Barrile

IPC: A61K31/5513 ,  A61K31/337 ,  A61K31/495 ,  A61P35/00

CPC classification number: A61K31/5513 ,  A61K31/337 ,  A61K31/495 ,  A61P35/00

Abstract: Provided herein are methods of potentiating an effect of an anti-cancer drug in a subject diagnosed with cancer, the method including administering to the subject a combination therapy including: an effective amount of 7-ethynyl-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one (BZD-1); and an anti-cancer drug.

公开(公告)号：US20240083905A1

公开(公告)日：2024-03-14

申请号：US18363933

申请日：2023-08-02

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade - Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61P25/22

CPC classification number: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20230103216A1

公开(公告)日：2023-03-30

申请号：US17886403

申请日：2022-08-11

Applicant: UWM Research Foundation, Inc. ,  The Trustees of Columbia University in the City of New York

Inventor： Alexander E. Arnold ,  Douglas C. Stafford ,  James M. Cook ,  Charles W. Emala ,  Gloria Forkuo ,  Rajwana Jahan ,  Revathi Kodali ,  Guanguan Li ,  Michael Rajesh Stephen

IPC: C07D487/14 ,  A61P11/06 ,  C07D487/04

Abstract: Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.

公开(公告)号：US20240374612A1

公开(公告)日：2024-11-14

申请号：US18690342

申请日：2022-09-08

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health

Inventor： Thomas Damien Prevot ,  Michael Jeffrey Marcotte ,  Etienne Laurent Sibille ,  James M. Cook ,  Guangan Li ,  Prithu Mondal ,  Md Yeunus Mian ,  Farjana Rashid

IPC: A61K31/5517 ,  A61P25/00 ,  C07D487/04

Abstract: 4H-Benzo[f]imidazo [1,5-a][1,4]diazepines substituted in the 3-position with an amide or oxadiazole and their pharmaceutical compositions display efficacy to enhance cognition and may have utility in the treatment of cognitive deficiencies, such as in neurodegenerative and neuropsychiatric disorders.

公开(公告)号：US11753412B2

公开(公告)日：2023-09-12

申请号：US17122745

申请日：2020-12-15

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade—Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61K31/5517 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28

CPC classification number: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20210309662A1

公开(公告)日：2021-10-07

申请号：US17122745

申请日：2020-12-15

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade - Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20210284649A1

公开(公告)日：2021-09-16

申请号：US16325080

申请日：2017-08-16

Applicant: UWM Research Foundation, Inc. ,  The Trustees of Columbia University in the City of New York

Inventor： Alexander E. Arnold ,  Douglas C. Stafford ,  James M. Cook ,  Charles W. Emala ,  Gloria Forkuo ,  Rajwana Jahan ,  Revathi Kodali ,  Guanguan Li ,  Michael Rajesh Stephen

IPC: C07D487/14 ,  A61P11/06 ,  C07D487/04

Abstract: Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.

公开(公告)号：US20200316087A1

公开(公告)日：2020-10-08

申请号：US16652914

申请日：2018-10-03

Applicant: UWM Research Foundation, Inc. ,  The Research Foundation for the State University of New York

Inventor： James M. Cook ,  Veera Venkata Naga Phani Babu Tiruveedhula ,  Jun-Xu Li

IPC: A61K31/5517 ,  A61K31/5513 ,  A61P25/22 ,  A61P25/08 ,  A61P23/00

Abstract: Combination therapy with a GABAA agonist and a α1β2/3γ2 GABA inhibitor is for the treatment of pain, epilepsy, or depression with reduced GABAA agonist-mediated adverse effects compared with GABAA agonist therapy alone. Effective doses of α1β2/3γ2 GABA inhibitor reduce GABAA agonist adverse effects without substantial inhibition of therapeutic efficacy.

公开(公告)号：US20190300534A1

公开(公告)日：2019-10-03

申请号：US16283926

申请日：2019-02-25

Applicant: UWM Research Foundation, Inc.

Inventor： James M. Cook ,  Michael Ming-Jin Poe ,  Kashi Reddy Methuku ,  Guanguan Li

IPC: C07D487/04

Abstract: Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

公开(公告)号：US09133141B2

公开(公告)日：2015-09-15

申请号：US14148959

申请日：2014-01-07

Applicant: Marquette University ,  UWM Research Foundation, Inc.

Inventor： James M. Cook ,  David A. Baker ,  Edward Merle Johnson, II ,  Wenyuan Yin ,  Ranjit Singh Verma

IPC: C07D271/06 ,  C07D249/08 ,  C07D413/12 ,  C07K5/062 ,  C07K5/103

CPC classification number: C07D271/06 ,  C07D249/08 ,  C07D413/12 ,  C07K5/0606 ,  C07K5/1008

Abstract: The present invention provides cysteine and cystine bioisosteres for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing such bioisosteres and methods of using the bioisosteres for treatment of schizophrenia and drug addiction.

Abstract translation: 本发明提供了用于治疗精神分裂症和药物成瘾的半胱氨酸和胱氨酸生物电子等排体。 本发明还包括含有这种生物电子等排体的药物组合物和使用生物电子等离子体治疗精神分裂症和药物成瘾的方法。